LENVIMA® (Lenvatinib) plus KEYTRUDA® (Pembrolizumab)

The FDA on August 10, 2021 approved the combination of LENVIMA® plus KEYTRUDA® for first-line treatment of adult patients with advanced Renal Cell Carcinoma (RCC). LENVIMA® is a product of Eisai Co., Ltd. and KEYTRUDA® is a product of Merck & Co.